drugset / Trial / NCT03715478
Multi-Center Study of GSK2857916 in Combination With Pomalidomide and Dex
Phase 1/2
Active not recruiting
120 enrolled
Canadian Myeloma Research Group
GlaxoSmithKline · collab
NaSequentialOpen-labelTreatment
Summary
This is a Phase 1/2, multi-centre, single-arm, open-label, dose-escalation study that will evaluate the safety and efficacy of IV GSK2857916 in combination with PO pomalidomide and low-dose PO dexamethasone in subjects with relapsed and/or refractory MM.
Timeline
- Start
- 2018-11-26
- Primary completion
- 2025-06-01
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Belantamab mafodotin | Monoclonal antibody | 1.92 mg/kg | Intravenous |
| Subject | Belantamab mafodotin | Monoclonal antibody | 2.5 mg/kg | Intravenous |
| Subject | Belantamab mafodotin | Monoclonal antibody | 3.4 mg/kg | Intravenous |
| Background | Dexamethasone | Small molecule | 20 mg | Oral |
| Background | Dexamethasone | Small molecule | 40 mg | Oral |
| Background | Pomalidomide | Other / unclassified | 4 mg | Oral |